A radioreceptor assay (RRA) was used to determine the neuroleptic plasma levels of 32 outpatients with schizophrenia receiving a high dose of neuroleptics (the equivalent of 18 mg or more of oral haloperidol per day) and undergoing a 50% partial and progressive reduction (ten percent each month for five months) in their medication. Plasma levels of neuroleptics were measured three times: before (T1) and immediately after the 50% reduction (T2) and five months later (T3). A linear correlation was observed between neuroleptic plasma levels obtained by RRA and the neuroleptic doses prescribed at T1 and T3. Furthermore, neuroleptic plasma levels were significantly lower at T3 than at T1. Concurrent evaluations of psychopathology were done using the Brief Psychiatric Rating Scale, and the results indicated that no correlation exists between neuroleptic plasma levels and the total rating scale scores at T1 but a significant correlation was observed at T3.
References
1.
HollisterLEStrategies for research in clinical psychopharmacology. In: MeltzerHY ed. Psychopharmacology: the third generation of progress.New York NY: Raven Press, 1987.
2.
KaneJM, RilkinA, WoenerM.Low dose neuroleptic treatment of outpatient schizophrenics: I. Preliminary results for relapse rates.Arch Gen Psychiatry1983; 40: 893–896.
3.
CreeseI, SnyderSHA simple and sensitive radioreceptor assay for antischizophrenic drugs in blood.Nature1977; 270: 180–182.
4.
MidhaKK, HawesEM, HubbardJ.W.The search for correlations between neuroleptic plasma levels and clinical outcome: a critical review. In: MeltzerHY ed. Psychopharmacology: the third generation of progress.New York NY: Raven Press, 1987.
CohenBM, LipinskiJF, HarrisP.Q.Clinical use of the radioreceptor assay for neuroleptics.Psychiatr Res1980; 1: 173–178.
7.
KrskaJ, SampathG, ShahA.Radio receptor assay of serum neuroleptic levels in psychiatric patients.Br J Psychiatry1986; 148: 187–193.
8.
TuneLE, CreeseI, DePauloJ.R.Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients.J Nerv Ment Dis1981; 169: 60–63.
9.
TuneLE, CoyleJTNeuroleptic drug level monitoring in psychiatry: focus on radioreceptor assay techniques.Ther Drug Monit1982; 4: 59–64.
10.
MailmanRB, PierceJP, CroftonK.M.Thioridazine and the neuroleptic radioreceptor assay.Biol Psychiatry1984; 19: 833–847.
11.
CohenBM, ChouinardG, WaternauxC.Plasma concentration of neuroleptic and serum prolactin in patients chronically receiving depot fluphenazine: no evidence of tolerance.Human Psychopharmacology1987; 2: 171–176.
12.
LeblancG, CormierHJ, VaillancourtS.Qui sont les patients traités en clinique externe avec des doses élevées de neuroleptiques?Can J Psychiatry1990; 35(1): 12–24.
13.
DavisJM, SchafferCB, KillianG.A.Important issues in the drug treatment of schizophrenia.Schizophr Bull1980; 66: 70–87.
14.
GelenbergAJPsychoses. In: GelenbergAJ, BassukEL, SchoonoverS.C. eds. The practitioner's guide to psychoactive drugs, third edition. New York NY: Plenum Medical Book Company, 1991.
KoGN, KorpiER, LinnoilaMOn the clinical relevance and methods of quantification of plasma concentrations of neuroleptics.J Clin Psychopharmacol1985; 5: 253–262.
19.
ContrerasS, AlexanderH, FaberR.Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.J Clin Psychopharmacol1987; 7: 95–98.
20.
CalilHM, AveryDH, HollisterL.E.Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations.Psychiatr Res1979; 1: 39–44.
21.
GuthrieS, LaneEA, LinnoilaMMonitoring of plasma drug concentrations in clinical psychopharmacology. In: Psychopharmacology: the third generation of progress.New York NY: Raven Press,1987.
Rivera-CalimlimL, GiftT, NasrallahH.A.Low plasma levels of CPZ in patients chronically treated with neuroleptics.Communications in Psychopharmacology1978; 2: 113–121.
24.
ForrestFM, ForrestIS, SerraMTModification of chlorpromazine metabolism by some other drugs frequently administered to psychiatric patients.Biol Psychiatry1970; 2: 53–58.
25.
JohnsonDAW, PasterskiG, LudlowJMThe discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences.Acta Psychiatr Scand1983; 67: 339–352.
BrancheyMH, BrancheyLB, RichardsonMAEffects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients.Am J Psychiatry1981; 138: 608–612.
28.
FaraoneSV, BrownWA, LaughrenTPSerum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.J Clin Psychiatry1987; 48: 151–154.
29.
SilverstoneT, CooksonJ, BallR.The relationships of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol.J Psychiatr Res1984; 18: 255–268.
30.
RimonR, AverbuchI, RozickP.Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.Psychopharmacology1981; 73: 197–199.
31.
BaldessariniRJ, CohenBM, TeicherMHSignificance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.Arch Gen Psychiatry1988; 45: 79–91.
32.
GarverDLNeuroleptic drug levels and antipsychotic effects: a difficult correlation; potential advantage of free (or derivative) versus total plasma levels.J Clin Psychopharmacol1989; 9: 277–281.
